Stock Research: Bio-Rad Laboratories

Independent, rules-based stock research to judge this stock's true performance: Cut through market noise and find high-growth or high-value gems from 8,000+ stocks worldwide.

Bio-Rad Laboratories

NYQ:BIO US0905722072
34
  • Value
    24
  • Growth
    49
  • Safety
    Safety
    96
  • Combined
    63
  • Sentiment
    11
  • 360° View
    360° View
    34
Unlock
What factors are driving this 360° View?
Subscribe to View
Company Description

Bio-Rad Laboratories develops, manufactures, and markets products for life science research and clinical diagnostics. It operates in the Life Science and Clinical Diagnostics industries. Its products are sold globally to hospital laboratories, diagnostic reference laboratories, and physician office laboratories. In the last fiscal year, the company had a market cap of $6784 million, profits of $1379 million, and revenue of $2567 million, with 7700 employees.

more

ANALYSIS: With an Obermatt 360° View of 34 (better than 34% compared with alternatives), overall professional sentiment and financial characteristics for the stock Bio-Rad Laboratories are below the industry average. The 360° View is based on consolidating four consolidated indicators, with three out of four metrics below average for Bio-Rad Laboratories. The only rank that is above average is the consolidated Safety Rank at 96, which means that the company has a financing structure that is safer than those of 96% comparable companies when looking at the amount of its debt, its refinancing requirements, and its ability to service debt. But the Value, Growth and Sentiment Ranks are all below average. The consolidated Value Rank has a less desirable rank of 24, which means that the share price of Bio-Rad Laboratories is on the high side compared with typical size in indicators such as revenues, profits, and invested capital. The consolidated Growth Rank also has a low rank of 49, which implies that the company exhibits below-average growth momentum when looking at financial metrics such as revenue, profit, and invested capital growth as well as stock returns. Finally, the consolidated Sentiment Rank is also low at a rank of 11, which means that professional investors are more pessimistic about the stock than for 89% of alternative investment opportunities. While Safety is strong, it’s not the most critical indicator, so we suggest proceeding with caution if you are considering this stock. ...read more

more
Index
D.J. US Health Care
S&P MIDCAP
Similar Add to Watchlist Similar See Similar Stocks
The higher the 360° View, the better the stock performed against its peers, considering all metrics. The 360° View represents an average of the other 5 ranks and is then scaled to a rank from 1 to 100. The shaded values are illustrative only.
Last update: 23-Apr-2026.

Make Sense of the Ranks

The higher, the better. For every stock, we judge its performance against its peers and rank it on a scale of 1 to 100. These ranks are percentiles: a rank of 75 means the company outperforms 75% of its peers in that specific area. The higher the rank, the better the stock stacks up against its peers.

Detailed and Historical Ranks

Deep dive into 15 detailed ranks and 3 years of history. Unlock the analysis.

Unlock Ranks

Unlock all 15 detailed ranks and historical data for 6,500+ stocks.

Subscribe to Unlock
Metrics Current 2025 2024 2023
Value
24 61 60 49
Growth
49 3 9 17
Safety
Safety
96 97 86 96
Sentiment
11 13 36 61
360° View
360° View
34 25 45 65
Unlock Similar Stocks

Unlock all 15 detailed ranks and historical data for 6,500+ stocks.

Subscribe to Unlock
Metrics Current 2025 2024 2023
Analyst Opinions
1 40 69 88
Opinions Change
4 8 50 50
Pro Holdings
n/a 31 24 65
Market Pulse
55 40 43 16
Sentiment
11 13 36 61
Unlock Similar Stocks

Unlock all 15 detailed ranks and historical data for 6,500+ stocks.

Subscribe to Unlock
Metrics Current 2025 2024 2023
Value
24 61 60 49
Growth
49 3 9 17
Safety Safety
96 97 86 96
Combined
63 64 50 51
Unlock Similar Stocks

Unlock all 15 detailed ranks and historical data for 6,500+ stocks.

Subscribe to Unlock
Metrics Current 2025 2024 2023
Price vs. Sales (P/S)
48 64 57 50
Price vs. Earnings (P/E)
12 32 47 10
Price vs. Book (P/B)
69 84 85 100
Dividend Yield
1 1 1 1
Value
24 61 60 49
Unlock Similar Stocks

Unlock all 15 detailed ranks and historical data for 6,500+ stocks.

Subscribe to Unlock
Metrics Current 2025 2024 2023
Revenue Growth
29 12 20 7
Profit Growth
67 26 34 68
Capital Growth
47 11 29 27
Stock Returns
59 51 27 55
Growth
49 3 9 17
Unlock Similar Stocks

Unlock all 15 detailed ranks and historical data for 6,500+ stocks.

Subscribe to Unlock
Metrics Current 2025 2024 2023
Leverage
71 60 62 82
Refinancing
79 70 63 49
Liquidity
82 64 63 81
Safety Safety
96 97 86 96

Similar Stocks

Discover high‑ranked alternatives to Bio-Rad Laboratories and broaden your portfolio horizons.

Walt Disney

NYQ:DIS
Country: USA
Industry: Movies & Entertainment
Size: XX-Large
Full Stock Analysis

ResMed

NYQ:RMD
Country: USA
Industry: Health Care Equipment
Size: X-Large
Full Stock Analysis

Corteva

NYQ:CTVA
Country: USA
Industry: Fertilizers & Agricultural Chemicals
Size: X-Large
Full Stock Analysis

Microsoft

NSQ:MSFT
Country: USA
Industry: Systems Software
Size: XX-Large
Full Stock Analysis

Frequently Asked
Questions

The company has high growth and safe financing but is expensive (low Value Rank) and has low market sentiment. This is a warning that the stock may be too expensive. This is for an experienced growth investor willing to risk overpaying, but only after conducting thorough research on future growth potential.

Obermatt provides unbiased stock analysis as a completely independent third party. We have no conflicts of interest with individual stock titles. Our data-driven analysis is based on algorithms honed over twelve years, giving you analysis that is free from personal bias and conflicts of interest.

The 360° View Rank indicates a company's overall performance across all major financial and non-financial metrics tracked by Obermatt. A 360° View Rank of 75 means the company is more well-rounded than 75% of similar companies. A high score indicates that the company is strong across the board; it is attractively priced, growing sustainably, financially stable, and well-regarded by the market. Learn more.

Become an Obermatt subscriber and see all of the similar stocks here.

The Obermatt Advantage

Ready to Elevate Your Investing?
Get Started Today

Choose the Obermatt subscription that best fits your needs.


30-day money back guarantee. Your subscription will renew until you cancel it, which you can do at any time.

What Our Customers Say

See how Obermatt improved their investing: